A single-center retrospective study (72) on the effects of ARBs and ACEIs on COVID-19 patients with pre-existing hypertension showed that ARBs/ACEIs treatment significantly reduced the concentrations of CRP [11.5 (4.0–58.2) vs. 33.9 (5.1–119.2); P = 0.049] and procalcitonin [0.061 (0.044–0.131) vs. 0.121 (0.052–0.295); P = 0.008], when compared with non-ARBs/ACEIs treatment. The gene discussed is CRP; the disease is COVID-19.